Compare iShares MSCI ACWI ETF (ACWI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Novartis AG — how do they compare? iShares MSCI ACWI ETF trades at $161.26, while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| ACWI | NVS | |
|---|---|---|
52-Week High | $161.44 | $168.62 |
52-Week Low | $132.04 | $119.31 |
Market Cap | — | $298.18B |
Sector | — | Health |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI (iShares MSCI ACWI ETF) trades at $161.44, up 0.84% with a bullish technical signal from moving averages, though oscillators show caution. The ETF benefits from strong global earnings growth and a forward P/E of 15.5x as of Seeking Alpha on July 7, 2026. Recent institutional activity includes Bank of New York Mellon adjusting its stake, reflecting ongoing investor interest in global equity exposure, particularly in technology sectors.
The outlook for ACWI is supported by robust EPS growth and technical momentum, but risks include market volatility and sector concentration. Investors may find opportunity in its diversified global holdings, though overbought conditions near resistance at $162 warrant monitoring for pullbacks to support at $160.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
